ycliper

Популярное

Музыка Кино и Анимация Автомобили Животные Спорт Путешествия Игры Юмор

Интересные видео

2025 Сериалы Трейлеры Новости Как сделать Видеоуроки Diy своими руками

Топ запросов

смотреть а4 schoolboy runaway турецкий сериал смотреть мультфильмы эдисон
Скачать

Who Lives Longer? Ozempic vs Mounjaro vs Retatrutide.

Автор: Dr. Amin Hedayat, MD

Загружено: 2026-11-21

Просмотров: 24782

Описание: Does Ozempic help you live longer? Semaglutide (Ozempic, Wegovy) has two trials that counted deaths against placebo, both in people who already had heart or kidney disease. Tirzepatide (Mounjaro, Zepbound) matched an older heart drug in people with diabetes. Retatrutide has weight data only.

Waitlist for UNINFLAMED™ (opens January 2, 2027): www.getuninflamed.com/

In this video I read the actual GLP-1 studies on longevity: the SELECT trial death count (17,604 people), the FLOW kidney trial, SURPASS-CVOT (tirzepatide vs dulaglutide), the retatrutide trial, and a 17-country study where grip strength predicted death better than blood pressure. That last one is a signal, not proof. Education only, not medical advice.

Subscribe so next Saturday's video finds you:    / @draminhedayat  
Watch next: What Happens When You Stop Ozempic or Mounjaro:    • What Happens When You Stop Ozempic or Moun...  

Where I landed: in SELECT, about 1 fewer person in 100 died on semaglutide over a little over 3 years. That count wasn't the main thing SELECT was built to test, so treat it as a strong hint. In FLOW, the kidney study, deaths from any cause were 20% lower, and that one was a planned test. With tirzepatide, 566 people died vs 669 on the older drug, but that wasn't the main test either, and nobody got a placebo. Nobody has counted deaths in healthy people who take these only for weight, and the studies stop at about 4 years. If you're on one, ask your doctor what you're taking it for: weight, heart, blood sugar, or kidneys.

No drug company or pharmacy pays me, including the pharmacies that mix their own versions of these shots. This video has no sponsor. It's education only, not medical advice for you personally, and watching or commenting doesn't create a doctor-patient relationship. Don't start or stop a medicine because of it; that's a decision for you and your doctor.

CHAPTERS
0:00 Who was still alive: 17,604 people counted
1:53 Who I am
2:30 Two loud crowds on GLP-1 drugs
2:54 SELECT trial: the semaglutide death count
5:05 Two cautions about that count
6:14 Beyond the scale: inflamed arteries
7:25 Who wasn't in the study
8:07 FLOW: the kidney study
9:28 Tirzepatide (Mounjaro, Zepbound) report card
11:27 Retatrutide report card
12:20 Grip strength: the test that beat blood pressure
13:35 Strength, muscle and these drugs
14:34 Why noticing is harder on a GLP-1
15:47 What I built
18:13 What I don't know
18:53 What to do this week
20:14 Close

STUDIES IN THIS VIDEO
1. SELECT. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med, 2023. Funded by Novo Nordisk. https://doi.org/10.1056/NEJMoa2307563
2. SELECT, every death and its cause. Scirica BM, et al. The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial. J Am Coll Cardiol, 2024. Funded by Novo Nordisk. https://doi.org/10.1016/j.jacc.2024.0...
3. SELECT, how much came from a smaller waist (the SELECT investigators). Deanfield J, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements. Lancet, 2025. Funded by Novo Nordisk. https://doi.org/10.1016/S0140-6736(25...
4. SELECT, the newer report. Colhoun HM, et al. Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial. Eur Heart J, 2026. Funded by Novo Nordisk. https://doi.org/10.1093/eurheartj/eha...
5. FLOW. Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med, 2024. Funded by Novo Nordisk. https://doi.org/10.1056/NEJMoa2403347
6. SURPASS-CVOT. Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med, 2025. Funded by Eli Lilly. https://doi.org/10.1056/NEJMoa2505928
7. SURPASS-CVOT, deaths from any cause. Nissen SE, et al. JAMA Cardiol, 2026. https://doi.org/10.1001/jamacardio.20...
8. TRIUMPH-1 (retatrutide). Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med, 2026. Funded by Eli Lilly. https://doi.org/10.1056/NEJMoa2604169
9. PURE, grip strength. Leong DP, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet, 2015. https://doi.org/10.1016/S0140-6736(14...
10. Self-monitoring review. Burke LE, et al. Self-monitoring in weight loss: a systematic review of the literature. J Am Diet Assoc, 2011. https://doi.org/10.1016/j.jada.2010.1...
11. Food-logging time. Harvey J, et al. Log Often, Lose More: Electronic Dietary Self-Monitoring for Weight Loss. Obesity, 2019. https://doi.org/10.1002/oby.22382
12. Still running, no results yet: SURMOUNT-MMO, tirzepatide vs placebo in adults with obesity and without diabetes. Sponsored by Eli Lilly. https://clinicaltrials.gov/study/NCT0...

#Ozempic #GLP1 #Longevity #Mounjaro #Semaglutide

Не удается загрузить Youtube-плеер. Проверьте блокировку Youtube в вашей сети.
Повторяем попытку...
Who Lives Longer? Ozempic vs Mounjaro vs Retatrutide.

Поделиться в:

Доступные форматы для скачивания:

Скачать видео

  • Информация по загрузке:

Скачать аудио

Похожие видео

© 2025 ycliper. Все права защищены.



  • Контакты
  • О нас
  • Политика конфиденциальности



Контакты для правообладателей: [email protected]